# AN Ventures

> AN Ventures is a VC fund in San Francisco backing Life Science and Biotechnology. See 5 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: San Francisco, United States
- Total investments: 5
- Last investment: Apr 2026
- Lead investor: 40%
- Last fund: Jul 2025
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/an-venture-partners
- Website: https://an.vc/en/#about

AN Ventures is a global biotech venture capital fund that builds companies in the global biotech ecosystem to maximize value creation and capture. AN Venture Partners comprises a dedicated team aiming to leverage Japanese science in the biotech field, with notable recent additions to their team.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Life Science | 2 | 40% |
| Biotechnology | 2 | 40% |
| Biopharma | 1 | 20% |
| Health Care | 1 | 20% |
| Therapeutics | 1 | 20% |

7 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 40% |
| Seed | 1 | 20% |
| Series B | 1 | 20% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Tortugas Neuroscience | Tortugas Neuroscience is a neurology-focused biotech company dedicated to developing effective medicines that address diseases of the brain. | $106M | Series A | Apr 21, 2026 |  |
| Imbria Pharmaceuticals | Imbria Pharmaceuticals’ mission is to translate our understanding of cellular metabolism into innovative medicines that improve the lives of patients with limited or inadequate treatment options. The company was founded by doctors and launched by an all doctor executive team motivated by the promise of bringing new therapies to people in need. Weare propelled by a deep scientific interest in cellular metabolism and the mitochondria, and are guided by both values and a code of business conduct built upon our commitment to always put the patients, families and communities we serve at the forefront of all that we do. |  | Series B | Nov 17, 2025 |  |
| Pahr Therapeutics | Pahr Therapeutics is a clinical-stage business whose goal is to create innovative ways to treat pulmonary arterial hypertension. | $14M | Seed | Jul 28, 2025 |  |
| Imbria Pharmaceuticals | Imbria Pharmaceuticals’ mission is to translate our understanding of cellular metabolism into innovative medicines that improve the lives of patients with limited or inadequate treatment options. The company was founded by doctors and launched by an all doctor executive team motivated by the promise of bringing new therapies to people in need. Weare propelled by a deep scientific interest in cellular metabolism and the mitochondria, and are guided by both values and a code of business conduct built upon our commitment to always put the patients, families and communities we serve at the forefront of all that we do. | $66.7M | Series B | Apr 10, 2025 |  |
| City Therapeutics | City Therapeutics is a biopharmaceutical company focusing on engineering next-generation small-interfering RNAs (siRNAs) to enhance RNAi-based therapies. The company develops a pipeline of innovative RNAi therapeutics aimed at addressing various disease indications. City Therapeutics prioritizes improving and expanding RNAi technology to achievebetter patient outcomes. The leadership team includes experienced scientists and industry professionals dedicated to advancing the field of RNA interference. | $135M | Series A | Oct 08, 2024 |  |

5 of 5 investments shown.

## Co-investors
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund, 3 deals together
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund, 2 deals together
- [Catalio Capital Management](https://shizune.co/investors/profile/catalio-capital-management) — VC Fund, 2 deals together
- [Cure Ventures](https://shizune.co/investors/profile/cure-ventures) — VC Fund, 2 deals together
- [Cytokinetics](https://shizune.co/investors/profile/cytokinetics-inc) — VC Fund, 2 deals together
- [Deep Track Capital](https://shizune.co/investors/profile/deep-track-capital) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does AN Ventures invest in?

AN Ventures invests primarily in Life Science, Biotechnology and Biopharma startups, most often at Series A and Seed stage. Most of the 5 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did AN Ventures last invest?

The most recent investment recorded for AN Ventures closed in Apr 2026. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co